Rockwell Medical Technologies (RMTI) Reports In-Line Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- S&P 500, Nasdaq futures slip as investors eye SK Hynix listing, Middle East risks
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Chardan Capital Still Positive on Rockwell Medical (RMTI) Following Q3 Results, Update
November 11, 2014 7:55 AM ESTChardan Capital affirms Rockwell Medical Technologies (Nasdaq: RMTI) at Buy with a price target of $27 following Q3 results.
Analyst Ling Wang noted that RMTI's loss of $0.10 per share was roughly in-line with the firm's $0.11 per share loss estimate.
Wang offered the following commentary:
FDA ODAC panel posted majority vote favoring the approval of Triferic. Last Wednesday, the ODAC panel voted favorably for the approval of RMTI's Triferic... More
